NCT06083116已完成1 期
Evaluation of Drug-drug Interaction Between Henagliflozin Proline and Hydrochlorothiazide in Healthy Chinese Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Steady-state pharmacokinetics parameters of Hydrochlorothiazide: Css, max
研究概览
简要总结
A single-center, single-arm, open-label, multi-dose, three-period study was conducted in healthy Chinese volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male;
- •Age 18-40 (including threshold);
- •Weight ≥ 50 kg, body mass index (BMI): 19.0~26.0 kg/m2 (including critical value);
- •Volunteers (and their spouses) must not plan for childbearing or sperm donation within one month prior to signing the informed consent form and from the period of taking the research drug until three months after stopping it;
- •Be able to communicate well with the investigators and understand and comply with the requirements in this study.
排除标准
- •Those have allergic constitution, or those with a known history of allergies to study drug or their excipients
- •Physical examination, vital signs, blood-routine examination, blood biochemistry, infectious disease screening, coagulation function, urine-routine examination, chest x-ray, B ultrasound and other examination results are abnormal and judged by the research doctor as clinically significant.
- •Hepatitis B surface antigen positive, hepatitis C antibody positive, HIV antibody positive, syphilis antibody positive;
- •Previous history of urinary tract infection or genital infection;
- •Previous history of hypoglycemia and other important diseases;
- •Those who have used other experimental drugs or medical devices within 3 months before screening;
- •Those who seek medical within 3 months prior to screening, which are judged by the research doctor to be unfit for participants;Those who have undergone any surgery within 6 months prior to screening;
- •Those who donate blood or other reasons of bleeding cause the total loss of blood more than 400mL or receive blood transfusions within 3 months before screening;
- •Have used any drugs in two weeks prior to taking the study drug;
- •Can not comply with the unified dietary arrangement;
- •Alcohol abuse, or those who smoke more 5 cigarettes per day in the 6 months prior to screening;
- •Positive alcohol breath test,or positive drug screening;
- •From 3 days before taking the study drug, subjects have xanthine-rich beverages or food, or grapefruit and other fruits or juices that may affect metabolism;
- •Subjects who are judged by researchers to be unsuitable for participating in this test.
研究组 & 干预措施
healthy subjects
Experimental
干预措施: Hydrochlorothiazide、Henagliflozin Proline (Drug)
结局指标
主要结局
Steady-state pharmacokinetics parameters of Hydrochlorothiazide: Css, max
时间窗: Day 4, Day 14
Steady-state pharmacokinetics parameters of Henagliflozin Proline: AUCτ,ss
时间窗: Day 10, Day 14
Steady-state pharmacokinetics parameters of Henagliflozin Proline: Css, max
时间窗: Day 10, Day 14
Steady-state pharmacokinetics parameters of Hydrochlorothiazide: AUCτ,ss
时间窗: Day 4, Day 14
次要结局
- Pharmacokinetics parameters of Hydrochlorothiazide: Tmax(Day 4, Day 14)
- Pharmacokinetics parameters of Henagliflozin Proline: t1/2(Day 10, Day 14)
- Pharmacokinetics parameters of Hydrochlorothiazide: t1/2(Day 4, Day 14)
- Pharmacokinetics parameters of Henagliflozin Proline: Tmax(Day 10, Day 14)
- Pharmacokinetics parameters of Henagliflozin Proline: CL/F(Day 10, Day 14)
- Pharmacokinetics parameters of Hydrochlorothiazide: CL/F(Day 4, Day 14)
- Adverse events(Day 4, Day 14)
- Accumulated urine electrolyte excretion 24 hours after administration(Day 4, Day 14)
- Urinary volume at 24 hours after administration(Day 4, Day 10, Day 14)
- Accumulated urine glucose excretion within 24 hours after administration(Day 10, Day 14)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in Subjects With Mild to Moderate HypertensionMild to Moderate HypertensionNCT01601470Novartis Pharmaceuticals28
已完成
1 期
A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and TopiramateEpilepsyNCT02283814Bial - Portela C S.A.32
已完成
1 期
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on ClopidogrelElevated Lipoprotein(a)Cardiovascular DiseasesNCT03392051Akcea Therapeutics18
已完成
1 期
Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy VolunteersStroke SequelaeStrokeNCT06090474Dr. Noah Biotech Inc.33
已完成
1 期
A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between "BR1015-1" and "BR1015-2" in Healthy VolunteersHypertensionNCT05097794Boryung Pharmaceutical Co., Ltd31